Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518081 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1PTPN1PDK1 | |
| SCHEMBL11654721 | 0.91 | ABCC4 (0.42) | LMNA | |
| SCHEMBL2000765 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL10932040 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1PTPN1PDK1 | |
| SCHEMBL31518207 | 0.87 | KMT2A (0.52) | ALDH1A1KMT2AMEN1PTPN1PDK1 | |
| SCHEMBL14784216 | 0.87 | KMT2A (0.52) | ALDH1A1KMT2AMEN1PTPN1PDK1 | |
| SCHEMBL11655151 | 0.85 | PPARA (0.43) | ALDH1A1KMT2AMEN1PDK1PDK2 | |
| SCHEMBL11655188 | 0.84 | SLC1A3 (0.45) | TDP1MAPT | |
| Ammonia Solution, Strong SCHEMBL27987206 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL11653742 | 0.82 | PPARA (0.49) | KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2755967-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038386-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013038386-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | CFTR, OPRD1, OPRK1 | ALDH1A1 1691/4885KMT2A 4300/4885MEN1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.